Übersicht unserer Publikationen

  • Koehl U, Sörensen J, Esser R, Zimmermann S, Grüttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 33:261-266 (2004).
  • Koehl U, Esser R, Zimmermann S, Tonn T, Kotchetkov R, Bartling T, Sörensen J, Grüttner HP, Bader P, Seifried E, Martin H, Lang P, Passweg J, Klingebiel T, Schwabe D. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr 217:345-350 (2005).
  • Zimmermann SY, Esser R, Rohrbach E, Klingebiel T, Koehl U. A novel four-colour flow cytometric assay to determine natural killer cell or T-cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20% of normal cells. J Immunol Methods 296:63-76 (2005).
  • Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, Erben S, Seidl C, Tonn T, Eggert A, Schramm A, Bader P, Klingebiel T, Lehrnbcher T, Passweg JR, Soerensen J, Schwabe D, Koehl U. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J of Immunotherapy 33 (2):200-210 (2010).
  • Kloess S, Huenecke S, Piechulek D, Esser R, Koch J, Brehm C, Soerensen J, Gardlowski T, Brinkmann A, Bader P, Passweg J, Klingebiel T, Schwabe D, Koehl U. IL-2 activated haploidentical NK cells restore NKG2D-mediated NK cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol 40(11):3255-67 (2010).
  • Brehm C, Huenecke C, Quaiser A, Esser R, Bremm M, Kloess S, Soerensen J, Kreyenberg H, Seidl C, Becker SA, Mühl H, Klingebiel T, Bader P, Passweg JR, Schwabe D, Koehl U. IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study. PLoS One. 2011;6(11):e27351 (2011).
  • Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies S, Aperlo-Iffland C, Huston J, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U*,. Wels W*. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumor cells of neuroectodermal origin. J of Cellular and Molecular Medicine J Cell Mol Med. 2012 Mar;16(3):569-81. doi: 10.1111/j.1582-4934.2011.01343.x. (2012) [* both authors contributed equally to this work]
  • Stern M, Passweg RJ, Meyer-Monard S, Esser R, Tonn T, Soerensen J, Paulussen M, Gratwohl A, Klingebiel T, Bader P, Tichelli A, Schwabe D, Köhl U. Preemptive Immunotherapy with Purified Natural Killer Cells after Haploidentical Stem Cell Transplantation. A Prospective Phase II Study in 2 Centers. Bone Marrow Transplantation 48(3):433-8. doi: 10.1038/bmt.2012 (2013)
  • Reiners K, Kessler J, Rothe A, Hansen H, Hucke C, Reusch U, Koehl U, Duerkop H, Engert A, Sauer M, Pogge von Strandmann E. Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients, Mol Therapy Apr;21(4):895-903. doi: 10.1038/mt.2013.14. Epub 2013 Mar 5 (2013).
  • Koehl U, Brehm C. Huenecke S, Zimmermann SY, Kloess S, Bremm M, Ullrich E, Soerensen J, Quaiser A, Erben S, Wunram C, Gardlowski T, Auth E, Tonn T, Seidl C, Meyer-Monard S, Stern M, Passweg J, Klingebiel T, Bader P, Schwabe D; Esser R. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Frontiers Oncology Front Front Oncol. 17;3:118. doi: 10.3389/fonc.2013.00118. (2013)
  • Vyase M, Hallek M, Köhl U, Pogge ES, Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer. Trends in Mol Med Feb; 20(2):72-82. doi: 10.1016/j.molmed.2013.10.006 (2014).
  • Brehm C, Huenecke S, Esser R, Kloess S, Quaiser A, Betz S, Zimmermann O, Soerensen J, Passweg JR, Klingebiel T, Schwabe D, Bader P, Koehl U. Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. Cancer Immunol Immunother. 2014 Aug;63(8):821-33. doi: 10.1007/s00262-014-1556-5 (2014).
  • Schönfeld K, Sahm C, Zhang C, Brendel C, Grez M, Naundorf S, Kühlcke K, Odendahl M, Tonn T, Nowakowska P, Bonig H, Seifried E, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Klingemann H, Rieger M, Schubert R, Wels W. Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor. Molecular Therapy Mol Ther. Feb;23(2):330-8. doi: 10.1038/mt.2014.219 (2015).
  • Glienke W, Esser R, Priesner C, Suerth J, Schambach A, Kloess S, Wels W, Grez M, Arseniev L, Koehl U. Advantages and application of CAR-expressing Natural Killer cells. Front Pharmacol. Feb 12;6:21. doi: 10.3389/fphar.2015.00021. eCollection Review (2015).
  • Suerth JD, Morgan M, Klöß S, Heckl D, Neudörfl C, Falk C, Koehl U, Schambach A. Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors. J Mol Med, Aug 25. [Epub ahead of print] (2015).
  • Klöß S, Chambron N, Gardlowski T; Arseniev L, Koch J, Esser R, Glienke W, Seitz O, Koehl U. Increased sMICA and TGF-b1 levels in HNSCC patients potentially impair NKG2D-dependent functionality of activated NK cells. OncoImmunology May 29;4(11):e1055993. eCollection Nov. (2015).
  • Kloess S, Chambron N, Gardlowski T, Weil S, Koch J, Esser R, Pogge-von-Strandmann E, Morgan M, Arseniev L, Seitz O, Koehl U. Cetuximab reconstitutes proinflammatory cytokine secretions and tumour-infiltrating capabilities of sMICA-inhibited NK cells in HNSCC tumour spheroids. Frontiers in Immunology in press